Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
- Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI).
- The Company is currently conducting a pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy.
- The study was initiated in January of 2021 and will take approximately 18 months to enroll fully.
- With the addition of this grant, Cellectar said over $46.8 million in cash and cash equivalents would provide a forecasted cash runway into Q3 2023.
- Waldenstrom's macroglobulinemia is lymphoma or cancer of the lymphatic system.
- The disease occurs in a type of white blood cell called a B-lymphocyte or B-cell, which matures typically into a plasma cell whose job is to manufacture immunoglobulins (antibodies) to help the body fight infection.
- Price Action: CLRB shares are down 0.82% at $0.87 during the market session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech Government News Penny Stocks Health Care Financing General
